Mechanisms contributing to venetoclax (VEN) resistance. (1) Gly101Val mutation (in black) acquired following venetoclax treatment as previously described. (2) New mutations (in red) identified concomitantly with Gly101Val, as described by Blombery and colleagues. (3) MCL-1 overexpression following VEN treatment. (4) Potential posttranslational modification (PTM) that may contribute to VEN resistance (eg, phosphorylation events).